<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/802F3522-BFFB-4B26-8B3F-E9D688945AC0"><gtr:id>802F3522-BFFB-4B26-8B3F-E9D688945AC0</gtr:id><gtr:name>Ablynx</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Infection</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/802F3522-BFFB-4B26-8B3F-E9D688945AC0"><gtr:id>802F3522-BFFB-4B26-8B3F-E9D688945AC0</gtr:id><gtr:name>Ablynx</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D5568E1D-EFE4-448E-821B-3B135E754B5D"><gtr:id>D5568E1D-EFE4-448E-821B-3B135E754B5D</gtr:id><gtr:firstName>Yasuhiro</gtr:firstName><gtr:surname>Takeuchi</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/650B4E61-0AB3-427E-ADA5-440E52DD8FE0"><gtr:id>650B4E61-0AB3-427E-ADA5-440E52DD8FE0</gtr:id><gtr:firstName>Nigel</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Temperton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3A2D1CFF-D14D-409F-8B2F-D87FFE363AF2"><gtr:id>3A2D1CFF-D14D-409F-8B2F-D87FFE363AF2</gtr:id><gtr:firstName>Robin</gtr:firstName><gtr:surname>Weiss</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0600369"><gtr:id>82224653-8A40-4802-AB26-B8C3ABB0199B</gtr:id><gtr:title>An alternative neutralization assay for H5N1 influenza A virus using retroviral pseudotypes</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0600369</gtr:grantReference><gtr:abstractText>The main protection against infection by influenza viruses is the presence of virus neutralizing antibodies in the blood. People who have recovered from flu have neutralizing antibodies to that strain of influenza virus, and effective flu jabs elicit similar protective antibodies. To aid the development and testing of vaccines against the new, deadly H5N1 influenza virus, we shall refine a novel neutralization test that uses an artificially constructed, harmless virus-like particle in place of the harmful influenza virus itself. Our test should be simple to use and will not require a high containment laboratory. It should offer a means to compare variation between sub-strains of H5N1 influenza viruses from different locations, and to evaluate whether candidate vaccines protect against all sub-strains. It may also offer a method to test candidate drugs that block influenza virus getting into cells.</gtr:abstractText><gtr:technicalSummary>The MRC/UCL Centre for Medical Molecular Virology includes a strong research platform on retrovirus neutralization and on retroviral vectors. We propose to apply this expertise to address H5N1 influenza neutralization. Immunity to influenza A virus infection is closely correlated to titres of neutralizing antibodies (NAb) that recognise haemagglutinin (HA). Conventional neutralization assays require titration of live influenza virus, and haemagglutination inhibition (HI) represents a less sensitive surrogate marker for neutralization. This project will develop and improve a neutralization test based on retroviral vectors that bear HA envelope antigens and carry an easily quantifiable reporter gene. The objective is to construct retroviral pseudotypes carrying a variety of H5N1 influenza HA antigens and to test their sensitivity to neutralization by natural human and avian sera, and by antisera raised against candidate H5N1 vaccines. The WHO has recommended the development of more sensitive and specific neutralization assays, and our approach could accelerate the testing of vaccines. Pseudotypes could also be applied to functional testing of the switch from avian to human sialic acid receptors, and to screening candidate drugs that inhibit HA-receptor interactions.</gtr:technicalSummary><gtr:fund><gtr:end>2008-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>224468</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ablynx</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>Use of HA pseudotypes for the evaluation of novel nanobody therapeutics against influenza H5N1</gtr:description><gtr:id>156976DA-8B1F-4162-9FCB-D38916BA54F5</gtr:id><gtr:impact>2 publications currently under peer review.</gtr:impact><gtr:outcomeId>3E40D2BC74F-1</gtr:outcomeId><gtr:partnerContribution>Panels of nanobodies with activity against H5N1 which can be used to study the kinetics of the neutralizing antibody response against this virus.</gtr:partnerContribution><gtr:piContribution>Design and construction of retroviral pseudotypes bearing HA envelopes from multiple H5N1 clades and subclades. Screening of nanobodies for neutralizing potential against H5N1.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>The use of influenza HA-pseudotyped particles for the serological evaluation of influenza vaccines</gtr:description><gtr:id>EA2C5CC1-14F6-42BA-A6EE-A92E7ED9C343</gtr:id><gtr:impact>PMID: 19665606</gtr:impact><gtr:outcomeId>C298BAC7509-1</gtr:outcomeId><gtr:partnerContribution>Synthetic genes and plasmids</gtr:partnerContribution><gtr:piContribution>I have trained members of Novartis Vaccines on the construction and evaluation of HA-pseudotyped particles for use in serological evaluation of influenza H5N1 vaccines. I have advised on further downstream serological applications of these pseudotyped particles.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>University Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>1E9FD627-3F5E-4DA8-8563-13EDC7A6ABC6</gtr:id><gtr:impact>150 Pre A-level students attended an open day with questions and discussions

N/A</gtr:impact><gtr:outcomeId>YsF7kGJnjSd</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>128978</gtr:amountPounds><gtr:country>Belgium, Kingdom of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>IWT Industry/Academia project grant</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Flemish Institute for Technological Research (VITO)</gtr:fundingOrg><gtr:id>BC2CC6B3-CFE4-4B8A-A754-7F3C59825197</gtr:id><gtr:outcomeId>7E6086922330</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EMA advisor on influenza serology</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>E09AD7F0-D34F-45D1-B84F-46783AC3C7D6</gtr:id><gtr:outcomeId>tpie1fyUxRV</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Development of a panel of HA pseudotyped retroviruses bearing HAs from different influenza subtypes (www.viralpseudotypeunit.info)</gtr:description><gtr:id>B84F9785-9925-44C9-B6F9-595C67C33303</gtr:id><gtr:impact>Ability to undertake serological assays for HPAI H5 and H7 viruses outside of high-containment.</gtr:impact><gtr:outcomeId>YLXJro6raf8</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Influenza HA pseudotype panel</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.viralpseudotypeunit.info</gtr:url><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Preparation of HIV-based vectors carrying different reporter genes (firefly and renilla luciferase, B-gal)</gtr:description><gtr:id>C4E3A7D4-A44B-4BEF-BF8D-2B009B496141</gtr:id><gtr:impact>1. Ability to perform pseudotype-based neutralization assays in a high-throughput format.
2. Ability to perform pseudotype-based neutralization assays using cheap reagents and instrumentation (B-gal).</gtr:impact><gtr:outcomeId>tBxomiBJ7uh</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>HIV vector readout</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A GFP based lentiviral vector system was optimized for high-throughput serological assays by replacing the GFP with either firefly luciferase, renilla luciferase or B-gal.</gtr:description><gtr:id>79424676-84B8-4C96-BFFA-E1637006130F</gtr:id><gtr:impact>PMID: 19665606 PMID: 19481117 PMID: 18753230</gtr:impact><gtr:outcomeId>3287A3D5371</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>HIV vectors optimized for serological applications.</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://europepmc.org/abstract/MED/19665606</gtr:url><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D3498B5C-0DBB-45F4-A07E-99269F2C0E23</gtr:id><gtr:title>Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a3c8292cef014ea5081874f71d6f03f"><gtr:id>5a3c8292cef014ea5081874f71d6f03f</gtr:id><gtr:otherNames>Mullarkey CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_15227_27_23589155</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58F6A1FF-B6B2-417E-911B-2ED5B2ED80A2</gtr:id><gtr:title>Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/654a6d10a06f182dd8f0d98e126c3340"><gtr:id>654a6d10a06f182dd8f0d98e126c3340</gtr:id><gtr:otherNames>Wright E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>pm_15227_17_18753230</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FD58414-7317-46A9-8EDE-905AF1C17B0F</gtr:id><gtr:title>Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d296ae9ff9dc398afaae0bc625303d4"><gtr:id>6d296ae9ff9dc398afaae0bc625303d4</gtr:id><gtr:otherNames>Iba?ez LI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>QDrQRnLwpjE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>996BB444-511D-40D9-9435-6A991DEABAA0</gtr:id><gtr:title>The use of equine influenza pseudotypes for serological screening.</gtr:title><gtr:parentPublicationTitle>Journal of molecular and genetic medicine : an international journal of biomedical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41a1121db9f971503c2bd7f8fa4d4247"><gtr:id>41a1121db9f971503c2bd7f8fa4d4247</gtr:id><gtr:otherNames>Scott S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1747-0862</gtr:issn><gtr:outcomeId>pm_15227_27_23515229</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D61F185E-DDFF-44C4-87C1-14A4ED35C636</gtr:id><gtr:title>Neutralizing monoclonal antibodies to different clades of Influenza A H5N1 viruses.</gtr:title><gtr:parentPublicationTitle>Journal of virological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dda8dca81310b7a2a0ab79fe69246742"><gtr:id>dda8dca81310b7a2a0ab79fe69246742</gtr:id><gtr:otherNames>Oh S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0166-0934</gtr:issn><gtr:outcomeId>C9EEB7FF62B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E077BDD8-46FF-4477-80A4-07910121C92B</gtr:id><gtr:title>Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fdf34da8a851c931921194f570eb429d"><gtr:id>fdf34da8a851c931921194f570eb429d</gtr:id><gtr:otherNames>Alberini I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>DCA579E830E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFBBBDC9-D831-4622-A565-14033FD6B20C</gtr:id><gtr:title>A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fef4e6185e9282a90000b15259fa70f"><gtr:id>5fef4e6185e9282a90000b15259fa70f</gtr:id><gtr:otherNames>Corti D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>nwgXeos19jC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F812926-2FD0-4F35-9299-D55059A8D4F9</gtr:id><gtr:title>Antigenic drift in H5N1 avian influenza virus in poultry is driven by mutations in major antigenic sites of the hemagglutinin molecule analogous to those for human influenza virus.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/09e37b5a63a7d409dcf63d9645e5eb71"><gtr:id>09e37b5a63a7d409dcf63d9645e5eb71</gtr:id><gtr:otherNames>Cattoli G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>rhPt9gUXnyN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F45A11E2-3501-4DC6-AAF7-3490E423FBC4</gtr:id><gtr:title>A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies.</gtr:title><gtr:parentPublicationTitle>Influenza and other respiratory viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/119090675276fd0e791054da5c3c73f5"><gtr:id>119090675276fd0e791054da5c3c73f5</gtr:id><gtr:otherNames>Temperton NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1750-2640</gtr:issn><gtr:outcomeId>371A1C60589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBD82969-3B6B-452F-A9FE-91021DCF03E3</gtr:id><gtr:title>Mutations in haemagglutinin that affect receptor binding and pH stability increase replication of a PR8 influenza virus with H5 HA in the upper respiratory tract of ferrets and may contribute to transmissibility.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01c37f21ca87cc081d1ef26d1e59b759"><gtr:id>01c37f21ca87cc081d1ef26d1e59b759</gtr:id><gtr:otherNames>Shelton H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>pm_15227_27_23486663</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3C841F9-D6AB-4AB1-BD21-6ECF65D01417</gtr:id><gtr:title>Infection with 2009 H1N1 influenza virus primes for immunological memory in human nose-associated lymphoid tissue, offering cross-reactive immunity to H1N1 and avian H5N1 viruses.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/faaa1b9f5cbcb490e72983f3bef14914"><gtr:id>faaa1b9f5cbcb490e72983f3bef14914</gtr:id><gtr:otherNames>Mahallawi WH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15227_27_23468498</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FFB0858-FD3A-4988-988B-23308C17906B</gtr:id><gtr:title>Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8872400fd9dff62c063a79bbf9476b2"><gtr:id>d8872400fd9dff62c063a79bbf9476b2</gtr:id><gtr:otherNames>Hultberg A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>VrLe6m4RNvk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61A124F3-1AB8-4D1A-85C1-938D57643BDA</gtr:id><gtr:title>The production and development of H7 Influenza virus pseudotypes for the study of humoral responses against avian viruses.</gtr:title><gtr:parentPublicationTitle>Journal of molecular and genetic medicine : an international journal of biomedical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49abb069b6a04d1ed3f3b7ac5be36a96"><gtr:id>49abb069b6a04d1ed3f3b7ac5be36a96</gtr:id><gtr:otherNames>Molesti E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1747-0862</gtr:issn><gtr:outcomeId>pm_15227_27_23577044</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83871D29-AEED-45B6-928E-D90C855563B1</gtr:id><gtr:title>In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses.</gtr:title><gtr:parentPublicationTitle>Antiviral research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc01595f4dba6322ecac442b53f832ca"><gtr:id>cc01595f4dba6322ecac442b53f832ca</gtr:id><gtr:otherNames>Su CY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0166-3542</gtr:issn><gtr:outcomeId>4DE520ADAF5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E777AD17-91C6-45A9-B53E-28F876071192</gtr:id><gtr:title>Human monoclonal antibodies in single chain fragment variable format with potent neutralization activity against influenza virus H5N1.</gtr:title><gtr:parentPublicationTitle>Antiviral research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/389ae5535d86f45314cac81f6a423281"><gtr:id>389ae5535d86f45314cac81f6a423281</gtr:id><gtr:otherNames>Ascione A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0166-3542</gtr:issn><gtr:outcomeId>0E5E27A0424</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D967D21-DD1A-4CCC-B039-8A3C4402FFC9</gtr:id><gtr:title>Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72b805334a8a5f9667cb62cfed9950f1"><gtr:id>72b805334a8a5f9667cb62cfed9950f1</gtr:id><gtr:otherNames>Loureiro S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>WVnSn6qYZUZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CEA586D-401D-420F-AFF5-77D94CE41816</gtr:id><gtr:title>The human Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes.</gtr:title><gtr:parentPublicationTitle>Journal of molecular and genetic medicine : an international journal of biomedical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f222d6ae49781457510ffb5c6eade3d"><gtr:id>6f222d6ae49781457510ffb5c6eade3d</gtr:id><gtr:otherNames>Ferrara F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1747-0862</gtr:issn><gtr:outcomeId>pm_15227_27_23577043</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B08C8D26-62AA-4722-A832-361AD86C0CEB</gtr:id><gtr:title>Comparative serological assays for the study of h5 and h7 avian influenza viruses.</gtr:title><gtr:parentPublicationTitle>Influenza research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49abb069b6a04d1ed3f3b7ac5be36a96"><gtr:id>49abb069b6a04d1ed3f3b7ac5be36a96</gtr:id><gtr:otherNames>Molesti E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2090-1380</gtr:issn><gtr:outcomeId>doi_15227_013_286158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7956369-2FDD-4F09-A393-01B923DC5E59</gtr:id><gtr:title>Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fef4e6185e9282a90000b15259fa70f"><gtr:id>5fef4e6185e9282a90000b15259fa70f</gtr:id><gtr:otherNames>Corti D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>VqvN1v1TrZH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1CCD86E-B8D8-4F33-B702-F303FF20BB57</gtr:id><gtr:title>Chicken interferon-inducible transmembrane protein 3 restricts influenza viruses and lyssaviruses in vitro.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75deba4059a8a10a422147d5bef9b2e2"><gtr:id>75deba4059a8a10a422147d5bef9b2e2</gtr:id><gtr:otherNames>Smith SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15227_27_24067955</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600369</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>